The aim of this study is to compare the blood levels achieved with a new formulation of AZD5672 to an existing formulation of AZD5672 used in previous studies
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
NONE
Enrollment
24
Research Site
Manchester, United Kingdom
Relative bioavailability of AZD5672 using PK variables AUC ss and C max ss
Time frame: Frequent sampling occasions during study periods, with intensive sampling occurring on days 7,14,21 and 28
Safety variables (adverse events, blood pressure, pulse, safety lab)
Time frame: AE assessed throughout whole the study, twice weekly assessment of BP, pulse and safety labs throughout study period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
100 mg (2 x 50 mg tablet (Reference Formulation)